Anti-tumor Effect of Activated Canine B Cells With Interleukin-21 and Anti-B Cell Receptor

Background/Aim: Recently, novel studies on the pivotal role of B cells in the tumor-microenvironment and anti-tumor immunity have been conducted. Additionally, Interleukin-21 (IL-21) and anti-B cell receptor (BCR) have been reported to stimulate B cells to secrete granzyme B, which exhibits cytotoxic effects on tumor cells. However, the direct anti-tumor effect of B cells is not yet fully understood in the veterinary field. This study is the first attempt in veterinary medicine to identify the immediate effect of B cells on tumor suppression and the underlying mechanisms involved. Materials and Methods: Canine B cells were isolated from peripheral blood and activated with IL-21 and anti-B cell receptor (BCR). The canine leukemia cell line GL-1 was co-cultured with B cells, and the anti-tumor effect was confirmed by assessing the changes in cell viability and apoptotic ratio. Results: When B cells were activated with IL-21 and anti-BCR, the secretion of granzyme B and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) increased. Simultaneously, the viability of GL-1 cells decreased, and the apoptotic ratio increased, particularly when co-cultured with activated B cells. Conclusion: The results demonstrated the direct anti-tumor effect of granzyme B-and TRAIL and its enhanced potential of B cells to inhibit tumor cell growth after activation with IL-21 and anti-BCR. This study is the first study dealing with immunomodulation in the canine tumor micro-environment.

[1]  E. Szegezdi,et al.  TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems , 2022, Cancers.

[2]  A. Chang,et al.  Emerging concepts regarding pro- and anti tumor properties of B cells in tumor immunity , 2022, Frontiers in Immunology.

[3]  N. Khan,et al.  B-Cell-Based Immunotherapy: A Promising New Alternative , 2022, Vaccines.

[4]  R. Ferris,et al.  Human B Cells Mediate Innate Anti-Cancer Cytotoxicity Through Concurrent Engagement of Multiple TNF Superfamily Ligands , 2022, Frontiers in Immunology.

[5]  G. Kinker,et al.  B Cell Orchestration of Anti-tumor Immune Responses: A Matter of Cell Localization and Communication , 2021, Frontiers in Cell and Developmental Biology.

[6]  J. Aguillón,et al.  Immunosuppressive Mechanisms of Regulatory B Cells , 2021, Frontiers in Immunology.

[7]  C. Sautès-Fridman,et al.  B cells and cancer: To B or not to B? , 2020, The Journal of experimental medicine.

[8]  P. Krebs,et al.  The multifaceted role of TRAIL signaling in cancer and immunity , 2020, The FEBS journal.

[9]  K. Shah,et al.  TRAIL of Hope Meeting Resistance in Cancer. , 2020, Trends in cancer.

[10]  A. Ghaderi,et al.  Granzyme B production by activated B cells derived from breast cancer-draining lymph nodes. , 2019, Molecular immunology.

[11]  Si-Si Wang,et al.  Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer , 2018, Cellular & Molecular Immunology.

[12]  M. McCarter,et al.  Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non–Small Cell Lung Cancer Patients , 2017, Cancer Immunology Research.

[13]  S. Pillai,et al.  B lymphocytes and cancer: a love-hate relationship. , 2016, Trends in cancer.

[14]  R. Morgan,et al.  Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses. , 2016, International immunology.

[15]  E. Diamandis,et al.  Cancer immunotherapy: the beginning of the end of cancer? , 2016, BMC Medicine.

[16]  K. Schwarz,et al.  CD4+ T Cell–Derived IL-21 and Deprivation of CD40 Signaling Favor the In Vivo Development of Granzyme B–Expressing Regulatory B Cells in HIV Patients , 2015, The Journal of Immunology.

[17]  Christopher J. Kane,et al.  Immunosuppressive plasma cells impede T cell-dependent immunogenic chemotherapy , 2015, Nature.

[18]  S. Qiu,et al.  Margin-Infiltrating CD20+ B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[19]  R. Kreienberg,et al.  Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. , 2013, Cancer research.

[20]  M. Hagn,et al.  Why do human B cells secrete granzyme B? Insights into a novel B-cell differentiation pathway , 2012, Oncoimmunology.

[21]  P. Watson,et al.  CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27− Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer , 2012, Clinical Cancer Research.

[22]  G. Nienhaus,et al.  Human B cells differentiate into granzyme B‐secreting cytotoxic B lymphocytes upon incomplete T‐cell help , 2012, Immunology and cell biology.

[23]  S. Knudsen,et al.  A 71-Gene Signature of TRAIL Sensitivity in Cancer Cells , 2011, Molecular Cancer Therapeutics.

[24]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[25]  E. S. St. Clair,et al.  Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. , 2011, Blood.

[26]  E. Křepela,et al.  Granzyme B-induced apoptosis in cancer cells and its regulation (review). , 2010, International journal of oncology.

[27]  B. Nelson,et al.  CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes , 2010, The Journal of Immunology.

[28]  J. Levitskaya,et al.  B cell receptor triggering sensitizes human B cells to TRAIL‐induced apoptosis , 2010, Journal of leukocyte biology.

[29]  S. Cullen,et al.  Granzymes in cancer and immunity , 2010, Cell Death and Differentiation.

[30]  Gen Sheng Wu.  TRAIL as a target in anti-cancer therapy. , 2009, Cancer letters.

[31]  Rebecca O Barnes,et al.  Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer , 2008, PloS one.

[32]  Mark J. Smyth,et al.  The TRAIL apoptotic pathway in cancer onset, progression and therapy , 2008, Nature Reviews Cancer.

[33]  W. Leonard,et al.  Interleukin 21: a cytokine/cytokine receptor system that has come of age , 2008, Journal of leukocyte biology.

[34]  J. Lieberman,et al.  Death by a thousand cuts: granzyme pathways of programmed cell death. , 2008, Annual review of immunology.

[35]  Bernd Jahrsdörfer,et al.  B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. , 2006, Blood.

[36]  A. Berner,et al.  NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. , 2006, American journal of clinical pathology.

[37]  J. Pers,et al.  Dysfunctional B cells in systemic lupus erythematosus. , 2004, Autoimmunity reviews.

[38]  M. Smyth,et al.  TRAIL and its receptors as targets for cancer therapy , 2004, Cancer science.

[39]  H G Bull,et al.  The three-dimensional structure of human granzyme B compared to caspase-3, key mediators of cell death with cleavage specificity for aspartic acid in P1. , 2001, Chemistry & biology.

[40]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[41]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[42]  A. Ghaderi,et al.  IL-21 and Anti-BCR Activated B Cells Induced Apoptosis in Breast Cancer Cell Line , 2022, Social Science Research Network.